Healthy Extracts Inc. (HYEX) Fair Value 2026

HYEX · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (38/100)

Quick Summary — As of 2026-08-27, Healthy Extracts Inc. (HYEX) trades at $1.17, versus a $0.32 median fair value across its 5 active models — 72.5% below the current price. QOC: 4.9/10. Value Trap Risk: 38/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $0.02.

Key Facts

Ticker
HYEX
Price
$1.17
Quality Score
4.9/10
Value Trap Risk
38/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.9/10 signals weak fundamentals

Is Healthy Extracts Inc. (HYEX) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Healthy Extracts Inc. (HYEX) appears overvalued as of : the median of 5 independent fair value estimates is $0.32, 72.5% below the current price of $1.17. Estimates range from $0.02 to $1.10. HYEX scores 4.9/10 on fundamental quality and 38/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. HYEX’s -72.5% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Healthy Extracts Inc. Stock in 2026? →

What Fair Value Does Each Model Give HYEX?

5 Intrinsic Value Models vs. Current Price ($1.17)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $0.02 -98.6%
Ensemble · Low Conviction
 $0.32 -72.5%
Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is HYEX's Fair Value Range?

Spread across 5 independent models · $0.02 to $1.10

CirclFi's 5 active models place Healthy Extracts Inc. (HYEX) between $0.02 and $1.10 per share, a spread of 336% of the median. The median of that range — $0.32 — is the fair value CirclFi publishes for HYEX, against a current price of $1.17.

Low · Bayesian DCFHigh · FTNN
$0.02median $0.32$1.10
Where the range comes from
Most bearish modelBayesian DCF$0.02
Most bullish modelFTNN Topology$1.10
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for HYEX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on HYEX, not a CirclFi price target. How each model works →

What Is Healthy Extracts Inc. (HYEX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Healthy Extracts Inc.'s intrinsic value is estimated at $0.32. Trading at its current price of $1.17, the valuation engine raises significant caution: 5 of 5 models flag downside risk, projecting a median implied return of -72.5%. The most optimistic model, FTNN, places fair value at $1.10 (-6.4%), while Bayesian DCF — the most conservative — estimates $0.02 (-98.6%). This +92.2% gap reflects genuine analytical uncertainty about Healthy Extracts Inc.'s intrinsic worth.

What Do the Models Say About HYEX?

5 of 13 models are currently active for HYEX. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for HYEX is $0.32 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.02 on its own, implying -98.6% downside from the current price. See which stocks rank higher →

How Does HYEX Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, HYEX ranks #80 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Healthy Extracts Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is HYEX a Value Trap?

CirclFi's Value Trap algorithm assigns HYEX a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Healthy Extracts Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Healthy Extracts Inc. earns a quality score of 4.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +92.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HYEX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HYEX's 5 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Healthy Extracts Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

APUSApimeds Pharmaceuticals US, Inc.QOC 5.0RGCRegencell Bioscience Holdings LimitedQOC 4.8CANNTrees CorporationQOC 5.1OWPCOne World Products, Inc.QOC 4.7IXHLIncannex Healthcare Inc.QOC 5.1BTAIBioXcel Therapeutics, Inc.QOC 4.7BGMBGM Group Ltd.QOC 1.9SUPNSupernus Pharmaceuticals, Inc.QOC 7.2INCRInterCure Ltd.QOC 6.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: APUS · RGC · CANN · OWPC · IXHL · BTAI · BGM · SUPN · INCR · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to HYEX?

7 companies across all industries closest to HYEX’s Quality of Company score of 4.9/10.

FUSEFusemachines Inc.QOC 4.9HMRHeidmar Maritime Holdings Corp.QOC 4.9MGAMMobile Global Esports Inc.QOC 4.9HQHAbrdn Healthcare InvestorsQOC 4.9AMBQAmbiq Micro, Inc.QOC 4.9BOEBlackRock Enhanced Global Dividend TrustQOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FUSE · HMR · MGAM · HQH · AMBQ · BOE · NVDA

Where Does HYEX Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

HYEX is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Healthy Extracts Inc.’s Valuation?

What is Healthy Extracts Inc.'s intrinsic value in 2026?

CirclFi puts Healthy Extracts Inc. (HYEX)'s intrinsic value at $0.32 — the median of 5 independent model estimates as of 2026-08-27, ranging from $0.02 to $1.10. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.02 on its own. The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HYEX overvalued or undervalued right now?

At $1.17, 0 of 5 active models suggest HYEX may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $0.32, 72.5% below the current price of $1.17 — a consensus view that HYEX is overvalued. The assessment depends on which methodology best fits Healthy Extracts Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 4.9 mean for HYEX?

Healthy Extracts Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HYEX?

CirclFi analyzes HYEX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on HYEX?

Of the 5 models currently active on HYEX, FTNN Topology is the most bullish at $1.10 per share, and Bayesian DCF is the most bearish at $0.02. CirclFi's published fair value for HYEX is the median of that range, $0.32, not either extreme. The gap between the two ends equals 336% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is HYEX a value trap in 2026?

Healthy Extracts Inc.'s Value Trap score is 38/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Healthy Extracts Inc. (HYEX) has a median fair value of $0.32 — 72.5% below the current price of $1.17 — as of 2026-08-27.” Source: circlfi.com/stock/HYEX/ · Methodology
Primary sources for this HYEX valuation
  • Financial statements: Healthy Extracts Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001630176) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HYEX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on HYEX.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for HYEX Unlock All 5 — $39/mo